unknown
Cegrinaso 200mg+30mg 24 tablets

Cegrinaso 200mg+30mg 24 tablets

Non-prescription drug indicated for the symptomatic treatment of nasal congestion associated with acute rhinosinusitis with suspected viral origin with headache and/or fever.

5726369
€9.05
Tax included
In stock (984 Items)
In stock (984 Items)
Add to wishlist Added to wishlist
 Calculate Shipping Cost

Cegrinaso 200mg+30mg is indicated for the symptomatic treatment of nasal congestion associated with acute rhinosinusitis with suspected viral origin with headache and/or fever. Cegrinaso is indicated for adults and adolescents aged 15 years and over.

Active substance : 200mg of ibuprofen and 30mg of pseudoephedrine hydrochloride.

Dosage and method of administration:

Adults and adolescents 15 years of age and older: 1 tablet (equivalent to 200 mg of ibuprofen and 30 mg of pseudoephedrine hydrochloride) every 6 hours if needed. For more severe symptoms, 2 tablets (equivalent to 400 mg ibuprofen and 60 mg pseudoephedrine hydrochloride) every 6 hours if necessary, up to a maximum daily dose of 6 tablets (equivalent to 1200 mg ibuprofen and 180 mg of pseudoephedrine hydrochloride). The maximum total daily dose of 6 tablets (equivalent to 1200 mg ibuprofen and 180 mg pseudoephedrine hydrochloride) must not be exceeded. The lowest effective dose for the shortest period of time needed to relieve symptoms should be used. The patient should consult a doctor if symptoms worsen. The maximum duration of treatment is 4 days for adults and 3 days for adolescents aged 15 years and over. In situations where the predominant symptoms consist of pain/fever or nasal congestion, administration of the substances in individual medications is preferable. Undesirable effects can be minimized by using the lowest effective dose for the shortest duration in order to achieve symptom control. Oral route. The tablets should be swallowed whole without chewing with a large glass of water, preferably during meals.

Contraindications:

Hypersensitivity to the active substance or to any of the excipients. Patients under 15 years of age; Women during the third trimester of pregnancy; Breastfeeding women; Patients with previous hypersensitivity reactions (eg bronchospasm, asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs); History of gastrointestinal bleeding or perforation related to previous NSAID therapy; Active or recurrent peptic ulcer/bleeding (two or more distinct and proven episodes of ulceration or bleeding); Cerebrovascular or other hemorrhages; Unexplained hematopoietic anomalies; severe liver failure; severe renal failure; Severe heart failure (NYHA Class IV); Serious cardiovascular pathologies, coronary heart disease (heart disease, hypertension, angina pectoris), tachycardia, hyperthyroidism, diabetes, pheochromocytoma; History of stroke or presence of risk factors for stroke (due to α-sympathomimetic activity of pseudoephedrine hydrochloride); Risk of angle-closure glaucoma; Risk of urinary retention related to disorders of the urethra and prostate; History of myocardial infarction; History of seizures; Systemic lupus erythematosus; Concomitant use of other vasoconstrictor medicinal products used as nasal decongestants, either administered orally or nasally (eg phenylpropanolamine, phenylephrine and ephedrine) and methylphenidate; Concomitant use of non-selective Monoamine Oxidase Inhibitors (MAOIs) (iproniazid) or use of monoamine oxidase inhibitors within the last two weeks.

If in doubt or if symptoms persist, consult your doctor or pharmacist.

In accordance with current legislation, non-prescription medicines in Portugal can only be delivered to the municipalities of Maia, Gondomar, Matosinhos, Porto, Santo Tirso, Trofa, Valongo and Vila do Conde. This limitation does not apply to shipments to other Member States of the European Union.

Top